Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 3:25 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Benzodiazepine Clear all
Active, not recruiting Phase 2 Interventional

Ketamine for Multiple Sclerosis Fatigue

NCT05378100
View directory record Official record
Conditions
Multiple Sclerosis Fatigue
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Sep 23, 2026, 3:25 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Cardio Risk of Acute Schizophrenia Olanzapine Duke

NCT00672464
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Olanzapine, Metformin, Simvastatin
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 60 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
2
States / cities
Butner, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 30, 2014 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 3 Interventional Results available

Music vs Midazolam During Preop Nerve Block Placement

NCT03069677
View directory record Official record
Conditions
Anxiety, Peripheral Nerve Block
Interventions
music, Midazolam
Other · Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 9, 2019 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

ESTIMATION OF THE EFFECT OF MULTIPLE DOSE PF-06651600 ON THE PHARMACOKINETICS OF SINGLE DOSE MIDAZOLAM AND EFAVIRENZ

NCT03762928
View directory record Official record
Conditions
Healthy Subjects
Interventions
PF-06651600, midazolam, efavirenz
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 25, 2019 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 1 Interventional

A DDI Study to Assess the Effect of INC280 on the PK of Midazolam and Caffeine in Patients With cMET-dysregulated Advanced Solid Tumors

NCT02520752
View directory record Official record
Conditions
cMET-dysregulated Advanced Solid Tumors
Interventions
INC280, Midazolam, Caffeine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
2
States / cities
Atlanta, Georgia • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 9, 2020 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First In Human Study Of PF-00184562 In Healthy Volunteers

NCT00150215
View directory record Official record
Conditions
Schizophrenia
Interventions
PF-00184562, Olanzapine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2006 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Dolutegravir (DTG) on PK of Cenicriviroc (CVC), and CVC on PK of DTG & on a Single Dose of Midazolam

NCT01827540
View directory record Official record
Conditions
HIV-infection/AIDS
Interventions
Cenicriviroc, Dolutegravir, Midazolam
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 8, 2014 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

First-Time-in-Human (FTIH) Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of VH4011499 in Healthy Participants

NCT05393271
View directory record Official record
Conditions
HIV Infections
Interventions
VH4011499, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Las Vegas, Nevada • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Sep 23, 2026, 3:25 PM EDT
Active, not recruiting Phase 1 Interventional

A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation

NCT04973163
View directory record Official record
Conditions
Solid Tumors, KRAS Mutation
Interventions
BI 1823911, BI 1701963, Midazolam
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
3
States / cities
New York, New York • Dallas, Texas • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

NCT00895921
View directory record Official record
Conditions
Diabetes
Interventions
Olanzapine, Aripiprazole
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
40 Years to 65 Years · Male only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 10, 2020 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 2Phase 3 Interventional Results available

D-cycloserine and Virtual Reality Exposure to Treat Iraq War Veterans With PTSD

NCT00356278
View directory record Official record
Conditions
Stress Disorder, Post Traumatic
Interventions
D-Cycloserine, Alprazolam, Virtual Reality Exposure Therapy, Placebo
Drug · Behavioral
Lead sponsor
Emory University
Other
Eligibility
21 Years to 65 Years
Enrollment
156 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 7, 2016 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Conscious Sedation Efficacy of the MKO Melt (Midazolam, Ketamine, Ondansetron)

NCT03653520
View directory record Official record
Conditions
Cataract
Interventions
Diazepam, Tramadol, Ondansetron, MKO melt
Drug
Lead sponsor
Avanti Anesthesia
Other
Eligibility
18 Years and older
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 30, 2018 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Abuse Potential of Intravenous Remimazolam Compared to Midazolam and Placebo in Recreational CNS Depressant Users

NCT04110535
View directory record Official record
Conditions
Abuse, Drug
Interventions
Remimazolam, Midazolam, Saline
Drug · Other
Lead sponsor
Paion UK Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
83 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Sep 30, 2019 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Not applicable Interventional Results available

Dexmedetomidine Versus Midazolam for Facilitating Extubation

NCT00744380
View directory record Official record
Conditions
Critical Illness
Interventions
Midazolam, Dexmedetomidine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Sep 23, 2026, 3:25 PM EDT
Completed No phase listed Observational

AduLt iatrogEnic withdRawal sTudy in the ICU (ALERT-ICU)

NCT04422808
View directory record Official record
Conditions
Withdrawal Syndrome, Iatrogenic Disease
Interventions
Not listed
Lead sponsor
Wilkes University
Other
Eligibility
18 Years and older
Enrollment
2,437 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Wilkes-Barre, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 28, 2022 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Effect of AZD5462 on the Pharmacokinetics of Midazolam, Rosuvastatin and Digoxin

NCT05395117
View directory record Official record
Conditions
Healthy Participants
Interventions
AZD5462, Midazolam, Rosuvastatin, Digoxin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Proof-of-Concept Trial on the Effect of Ketamine on Fatigue

NCT04141696
View directory record Official record
Conditions
Fatigue
Interventions
Ketamine, Midazolam
Drug
Lead sponsor
National Institute of Nursing Research (NINR)
NIH
Eligibility
18 Years to 70 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 14, 2025 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Ketamine Versus Etomidate for Procedural Sedation for Pediatric Orthopedic Reductions

NCT00596050
View directory record Official record
Conditions
Conscious Sedation Failure During Procedure
Interventions
ketamine and midazolam, etomidate, fentanyl, and lidocaine
Drug
Lead sponsor
Drexel University College of Medicine
Other
Eligibility
5 Years to 18 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Sep 23, 2026, 3:25 PM EDT
Recruiting Phase 1 Interventional

An Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis

NCT07665723
View directory record Official record
Conditions
Active Ulcerative Colitis
Interventions
Afimkibart, Caffeine, Warfarin, Omeprazole, Dextromethorphan, Midazolam, Vitamin K
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
3
States / cities
Chula Vista, California • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 1 Interventional

Parallel Group, Multiple Dose Pharmacokinetics Study of Five Antipsychotic Medications in Psychiatric Participants

NCT02087579
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Bipolar Disorder, Depressive Disorder
Interventions
Aripiprazole, oral formulation, Olanzapine, oral formulation, Paliperidone, oral formulation, Paliperidone, LAI, Quetiapine, oral formulation, Risperidone, oral formulation, Risperidone, LAI
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 70 Years
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
6
States / cities
Garden Grove, California • Kissimmee, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2015 · Synced Sep 23, 2026, 3:25 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Safety and PK of VH4770359 in Healthy Participants

NCT07525544
View directory record Official record
Conditions
HIV Infections
Interventions
VH4770359, Placebo, Midazolam
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
214 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 23, 2026, 3:25 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

NCT04278404
View directory record Official record
Conditions
Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension, Urinary Tract Infections in Children, Hypertension, Pain, Hyperphosphatemia, Primary Hyperaldosteronism, Edema, Hypokalemia, Heart Failure, Hemophilia, Menorrhagia, Insomnia, Pneumonia, Skin Infection, Arrythmia, Asthma in Children, Bronchopulmonary Dysplasia, Adrenal Insufficiency, Fibrinolysis; Hemorrhage, Attention Deficit Hyperactivity Disorder, Multisystem Inflammatory Syndrome in Children (MIS-C), Kawasaki Disease, Coagulation Disorder, Down Syndrome
Interventions
The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
Drug
Lead sponsor
Duke University
Other
Eligibility
0 Years to 20 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2026
U.S. locations
49
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 40 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 1 Interventional

A Phase I Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of GSK2118436 in Subjects With Solid Tumors

NCT00880321
View directory record Official record
Conditions
Cancer
Interventions
GSK2118436, Midazolam
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
4
States / cities
Los Angeles, California • New York, New York • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 23, 2026, 3:25 PM EDT
Completed Phase 4 Interventional Results available

Telmisartan as an Adjunctive Treatment for Metabolic Problems in Patients With Schizophrenia

NCT00981526
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Telmisartan, Placebo, Clozapine, Olanzapine
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
18 Years to 65 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 18, 2018 · Synced Sep 23, 2026, 3:25 PM EDT